Arcturus Therapeutics Holdings, Inc. (ARCT)

Arcturus Therapeutics Holdings, Inc. stock price has experienced significant fluctuations, declining by 60.83% over the past year and 43.26% over the past six months. In October 2025, the stock plunged due to disappointing Phase 2 data for ARCT-032. In September 2025, a "golden cross" technical signal occurred. In November 2025, Citi lowered its price target, while Wells Fargo maintained a "Buy" rating, and Piper Sandler maintained an "Overweight" recommendation. In January 2026, the company presented at the 44th Annual J.P. Morgan Healthcare Conference.

There is no explicit information on the demand seasonality for Arcturus Therapeutics' specific products or services, but stock performance indicates some monthly seasonality. Historically, buying ARCT stock in June has shown the highest probability of a positive return, while December has the lowest probability. This refers to stock seasonality and not necessarily the seasonality of demand for the company's developing pharmaceutical products or vaccines.

Arcturus Therapeutics Holdings, Inc. is an American RNA medicines biotechnology company focused on discovering, developing, and commercializing therapeutics for rare and infectious diseases. The company operates in the Healthcare sector, specifically within the Biotechnology and Pharmaceutical industries, utilizing its LUNAR® and STARR™ technology platforms. Its product pipeline includes KOSTAIVE (ARCT-154) for COVID-19, ARCT-810 (LUNAR-OTC) for ornithine transcarbamylase deficiency, ARCT-032 (LUNAR-CF) for cystic fibrosis, ARCT-2138 (LUNAR-FLU) for seasonal influenza, ARCT-2304 (LUNAR-H5N1) for Pandemic Influenza, and ARCT-2301 and ARCT-2303 for COVID-19.

Arcturus Therapeutics Holdings, Inc. is headquartered in San Diego, California, USA. The company has an international presence through its products and partnerships, including a joint venture in Japan for mRNA manufacturing. Its COVID-19 vaccine, Kostaive, has received marketing approval in Japan and the European Union.

Arcturus Therapeutics' brand reputation has been influenced by both positive developments and setbacks. Positive Phase 2 interim data for ARCT-810 and the authorization of Kostaive in Japan and the European Union enhanced the company's credibility. However, disappointing interim data from the ARCT-032 clinical trial negatively impacted its reputation, leading to concerns about potential delays and patent defense challenges.

Arcturus Therapeutics Holdings Inc. is primarily owned by institutional shareholders, who hold between 86.6% and 91.01% of the company's shares. Major institutional owners include Federated Hermes, Inc., BlackRock, Inc., Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Management Americas, Inc., Vanguard Group Inc., ARK Investment Management LLC, Balyasny Asset Management Llc, and State Street Corp. The largest individual shareholder is Joseph E. Payne, who owns 5.21% of the company.